Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:16 PM
Ignite Modification Date:
2025-12-24 @ 3:16 PM
NCT ID:
NCT02781792
Eligibility Criteria:
Inclusion Criteria:
* Newly diagnosed and recurrent high grade gliomas (WHO grades III \& IV) and high risk WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide therapy.
* Scheduled to receive adjuvant temozolomide therapy after having completed concurrent temozolomide and radiation therapy.
* At least 18 years of age.
* Karnofsky performance status ≥ 60%
* Ability to understand and willingness to sign an IRB approved written informed consent document
Exclusion Criteria:.
-Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02781792
Study Brief:
Protocol Section:
NCT02781792